open access

Vol 11, No 6 (2015)
Review paper
Published online: 2016-03-08
Get Citation

Early and late follow-up of patients with Hodgkin’s lymphoma. Recommendations of the Polish Lymphoma Research Group

Paweł Kurczab, Anna Czyż, Elżbieta Turska, Joanna Drozd-Sokołowska, Edyta Subocz, Agnieszka Szymczyk, Waldemar Tomczak, Jadwiga Hołojda, Wojciech Jurczak, Jan Walewski, Jan Maciej Zaucha
Oncol Clin Pract 2015;11(6):300-309.

open access

Vol 11, No 6 (2015)
REVIEW ARTICLES
Published online: 2016-03-08

Abstract

Post-treatment follow-up of patients with Hodgkin’s lymphoma has not yet been fully optimised and is still based mainly on clinical practice and experience. During the first years of follow-up, the principal aims are to detect relapse and monitor any post-treatment complications or side effects. Such as they are, current guidelines on follow-up are herein considered and discussed, together with those now recommended by the Polish Lymphoma Research Group.

Abstract

Post-treatment follow-up of patients with Hodgkin’s lymphoma has not yet been fully optimised and is still based mainly on clinical practice and experience. During the first years of follow-up, the principal aims are to detect relapse and monitor any post-treatment complications or side effects. Such as they are, current guidelines on follow-up are herein considered and discussed, together with those now recommended by the Polish Lymphoma Research Group.

Get Citation

Keywords

Hodgkin’s lymphoma, follow-up, relapse, adverse events of treatment

About this article
Title

Early and late follow-up of patients with Hodgkin’s lymphoma. Recommendations of the Polish Lymphoma Research Group

Journal

Oncology in Clinical Practice

Issue

Vol 11, No 6 (2015)

Article type

Review paper

Pages

300-309

Published online

2016-03-08

Bibliographic record

Oncol Clin Pract 2015;11(6):300-309.

Keywords

Hodgkin’s lymphoma
follow-up
relapse
adverse events of treatment

Authors

Paweł Kurczab
Anna Czyż
Elżbieta Turska
Joanna Drozd-Sokołowska
Edyta Subocz
Agnieszka Szymczyk
Waldemar Tomczak
Jadwiga Hołojda
Wojciech Jurczak
Jan Walewski
Jan Maciej Zaucha

References (68)
  1. Wróbel T, Chłoniak Ho. Hodgkina. In: Krzakowski M, Potemski P, Warzocha K, Wysocki P. ed. Onkologia Kliniczna, t. III. 2015: 1423.
  2. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma, Version 2.2015. www.nccn.org.
  3. Radford JA, Eardley A, Woodman C, et al. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997; 314(7077): 343–346.
  4. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol. 1997; 15(3): 1123–1130.
  5. Ha CS, Hodgson DC, Advani R, et al. ACR appropriateness criteria follow-up of Hodgkin lymphoma. J Am Coll Radiol. 2014; 11(11): 1026–1033.e3.
  6. Dryver ET, Jernström H, Tompkins K, et al. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer. 2003; 89(3): 482–486.
  7. Xavier MF, Schuster SJ, Andreadis C, et al. Detection of relapse in diffuse large B-cell lymphoma (DLBCL) and Hodgkin’s lymphoma (HL): observations andimplications for post-remission radiologic surveillance. ASH Ann Meet Abstr. 2006; 108: 2428.
  8. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009; 27(11): 1781–1787.
  9. Mocikova H, Obrtlikova P, Vackova B, et al. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol. 2010; 21(6): 1222–1227.
  10. El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica. 2012; 97(6): 931–936.
  11. Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010; 116(16): 3835–3842.
  12. Maeda LS, Horning SJ, Iagaru AH, et al. Role of FDG-PET/CT Surveillance for Patients with Classical Hodgkin’s Disease in First Complete Response: The Stanford University Experience. ASH Ann Meet Abstr. 2009; 114: 1563.
  13. Petrausch U, Samaras P, Veit-Haibach P, et al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol. 2010; 21(5): 1053–1057.
  14. Basciano BA, Moskowitz C, Zelenetz AD. Impact of routine surveillance imaging on the outcome of patients with relapsed Hodgkin lymphoma. ASH Ann Meet Abstr. 2009; 114: 1558.
  15. Friedmann AM, Wolfson JA, Hudson MM, et al. Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy. Pediatr Blood Cancer. 2013; 60(9): 1458–1463.
  16. Voss SD, Chen Lu, Constine LS, et al. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012; 20(30): 2635–2640.
  17. Dann EJ, Berkahn L, Mashiach T, et al. Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. Br J Haematol. 2014; 164(5): 694–700.
  18. Picardi M, Pugliese N, Cirillo M, et al. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures. Radiology. 2014; 272(1): 262–274.
  19. Cardis E, Vrijheid M, Blettner M, et al. The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: estimates of radiation-related cancer risks. Radiat Res. 2007; 167(4): 396–416.
  20. Crowley MP, O’Neill SB, O’Neill DC et al. Radiation Exposure From Diagnostic Imaging in Patients with Lymphoma — The Cost Of The Cure? 55 th ASH annual Meeting 2013, Abstract 557 from session 901: Health Services and Outcomes Research: Survivorship and Standardization of Care.
  21. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003; 21(18): 3431–3439.
  22. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007; 25(12): 1489–1497.
  23. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol. 2011; 29(31): 4096–4104.
  24. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006; 17(12): 1749–1760.
  25. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003; 95(13): 971–980.
  26. De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009; 27(26): 4239–4246.
  27. Elkin EB, Klem ML, Gonzales AM, et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011; 29(18): 2466–2473.
  28. Ng AK, Garber JE, Diller LR, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013; 31(18): 2282–2288.
  29. Saslow D, Boetes C, Burke W, et al. American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57(2): 75–89.
  30. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002; 94(3): 182–192.
  31. Wattson DA, Hunink MG, DiPiro PJ, et al. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol. 2006; 17(5): 785–793.
  32. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009; 27(27): 4548–4554.
  33. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002; 100(6): 1989–1996.
  34. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109(5): 1878–1886.
  35. Carver JR, Shapiro CL, Ng A, et al. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007; 25(25): 3991–4008.
  36. Girinsky T, M'Kacher R, Lessard N, et al. Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis. Int J Radiat Oncol Biol Phys. 2014; 89(1): 59–66.
  37. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993; 270(16): 1949–1955.
  38. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003; 290(21): 2831–2837.
  39. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003; 42(4): 743–749.
  40. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007; 25(1): 43–49.
  41. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2005; 23(27): 6508–6515.
  42. van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015; 175(6): 1007–1017.
  43. Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol. 1994; 30(1): 43–54.
  44. Chen AB, Punglia RS, Kuntz KM, et al. Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. J Clin Oncol. 2009; 27(32): 5383–5389.
  45. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991; 325(9): 599–605.
  46. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000; 85(9): 3227–3232.
  47. Koh ES, Sun A, Tran TuH, et al. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2006; 66(1): 223–228.
  48. Ng AK, Li S, Neuberg D, et al. A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol. 2008; 19(10): 1754–1758.
  49. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005; 23(30): 7614–7620.
  50. Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007; 137(6): 545–552.
  51. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007; 18(2): 376–380.
  52. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013; 14(13): 1348–1356.
  53. Haverkamp H, Böll B, Eichenauer DA, et al. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials. J Clin Oncol. 2015; 33(22): 2430–2436.
  54. Johnson PW, Federico M, Fossa A, et al. Response rates and toxicity of response-adapted therapy in advanced Hodgkin lymphoma: Initial results from the International RATHL Study. Haematologica. 2013; 98: 2.
  55. Behringer K, Goergen H, Hitz F, et al. German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015; 385(9976): 1418–1427.
  56. Knobel H, Håvard Loge J, Lund MB, et al. Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol. 2001; 19(13): 3226–3233.
  57. Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007; 25(1): 11–15.
  58. Kulkarni SS, Sastry PS, Saikia TK, et al. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol. 1997; 20(4): 354–357.
  59. Behringer K, Breuer K, Reineke T, et al. German Hodgkin's Lymphoma Study Group. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005; 23(30): 7555–7564.
  60. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008; 111(1): 71–76.
  61. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013; 31(6): 684–691.
  62. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013; 161(1): 76–86.
  63. Gopal AK, Chen R, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30(18): 2183–2189.
  64. Gopal AK, Bartlett NL, Forero-Torres A, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014; 55(10): 2328–2334.
  65. Forero-Torres A, Bartlett NL, Berryman RB, et al. Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leuk Lymphoma. 2015; 56(4): 1151–1153.
  66. Moskowitz CH, Nademanee A, Masszi T, et al. AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385(9980): 1853–1862.
  67. Wróbel T. Chłoniak Hodgkina. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013 rok. Onkol Prakt Klin. 2013; 9(suppl B): 989.
  68. Eichenauer DA, Engert A, André M, et al. ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: iii70–iii75.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl